Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Vertex Pharmaceuticals reported pivotal pediatric data for CASGEVY for young children with severe sickle cell disease and beta thalassemia. The company released positive long term and very early age group results for cystic fibrosis therapies ALYFTREK and TRIKAFTA. Vertex initiated regulatory reviews to expand indications into younger populations across multiple regions.

These updates come with Vertex Pharmaceuticals (NasdaqGS:VRTX) shares trading at $445.04 and a value score of 4, following a 27.5% return over 3 years and 136.3% over 5 years. The stock is slightly down 1.6% year to date and 3.3% over 1 year, providing context as the company reports new clinical and regulatory developments in its core therapy areas.

For investors tracking long term product potential, the new pediatric data and regulatory filings show how Vertex is working to broaden use of its existing treatments into younger age groups. The scope and timing of any impact on revenue or valuation will depend on regulatory decisions, real world uptake and competitor activity in similar indications.

Stay updated on the most important news stories for Vertex Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Vertex Pharmaceuticals.NasdaqGS:VRTX Earnings & Revenue Growth as at Jun 2026

We've flagged 0 risks for Vertex Pharmaceuticals. See which could impact your investment.

Investor Checklist

Quick Assessment

✅ Price vs Analyst Target: At US$445.04 versus a US$548.69 analyst target, the stock trades about 23% below consensus. ✅ Simply Wall St Valuation: Simply Wall St values the shares higher, with the stock trading 45.8% below its estimated fair value. ❌ Recent Momentum: The 30 day return is slightly negative, with the share price down 0.7% over that period.

There's only one way to know the right time to buy, sell or hold Vertex Pharmaceuticals. Head to Simply Wall St's company report for the latest analysis of Vertex Pharmaceuticals's Fair Value.

Key Considerations

📊 Pivotal pediatric CASGEVY data and earlier age cystic fibrosis results strengthen the case that Vertex is extending its existing franchises into younger patient groups. 📊 Watch regulatory decisions across regions, pediatric enrollment trends, and any updates to revenue or earnings guidance linked to these new indications. ⚠️ The key risk is execution around approvals, access and uptake in very young patients, where safety perceptions, payer decisions and competing therapies can all influence outcomes.

Story Continues

Dig Deeper

For the full picture including more risks and rewards, check out the complete Vertex Pharmaceuticals analysis. Alternatively, you can check out the community page for Vertex Pharmaceuticals to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include VRTX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Is VRTX a good stock to buy? We came across a bullish thesis on Vertex Pharmaceuticals Incorporated on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on VRTX. Vertex Pharmaceuticals Incorporated's share was trading at $445.77 as of June 9th. VRTX’s trailing and forward P/E were 26.46 and 23.47 respectively according to Yahoo Finance.Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data

Pressmaster/Shutterstock.com

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. VRTX is being mispriced by the market, which continues to frame it narrowly as a high-quality but mature cystic fibrosis company, despite it evolving into a broader, pipeline-driven biotech with multiple late-stage growth drivers. The core cash engine remains its cystic fibrosis franchise, which targets the full spectrum of cystic fibrosis disease caused by CFTR gene mutations.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

This franchise, led by Trikafta, effectively treats the underlying biology of entire cystic fibrosis rather than just managing symptoms, resulting in near-monopoly positioning, exceptional durability, and long-duration recurring revenues as patients remain on therapy for life. This alone generates highly visible, high-margin cash flows that justify a substantial portion of Vertex’s valuation and give it a structurally advantaged funding base.

However, the bull case is increasingly driven by what this cash engine enables. Vertex has successfully used cystic fibrosis profits to fund a diversified pipeline, headlined by suzetrigine, a first-in-class non-opioid pain drug with a novel mechanism of action recently approved for acute pain.

This opens access to a massive and underpenetrated pain market, with meaningful upside optionality if development in chronic pain succeeds, significantly expanding the total addressable market. Beyond pain, Vertex is advancing programs in kidney disease, Type 1 diabetes through islet cell therapy collaboration, and AATD, several of which have Phase 3 readouts expected in 2026 and 2027, providing multiple near- to medium-term catalysts.

The market continues to value Vertex as if it is solely dependent on entire cystic fibrosis, ignoring the compounding optionality from its expanding pipeline. As these programs mature and clinical validation accumulates, the company’s earnings base, growth profile, and valuation multiple are likely to re-rate meaningfully. At current levels, Vertex offers a rare combination of dominant franchise cash flow, underappreciated pipeline depth, and asymmetric long-term upside.

Story Continues

Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy commercialization and pipeline optionality in gene editing and oncology. CRSP’s stock price has appreciated by approximately 25.65% since our coverage. Variant_Invest shares a similar view but emphasizes Vertex Pharmaceuticals Incorporated (VRTX) and its cystic fibrosis cash engine funding diversified late-stage pipeline catalysts, highlighting a broader reinvestment-driven biotech model.

Vertex Pharmaceuticals Incorporated is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 68 hedge fund portfolios held VRTX at the end of the first quarter which was 64 in the previous quarter. While we acknowledge the risk and potential of VRTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VRTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

Disclosure: None.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

• Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent with the durable benefits established in patients 12 years and older -

• Data simultaneously published in the New England Journal of Medicine -

• Regulatory review underway in the United States to expand the use of CASGEVY, and Vertex has recently completed submissions in the Kingdom of Saudi Arabia and United Kingdom -

BOSTON, June 11, 2026--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent patients. These data were presented at the European Hematology Association (EHA) Congress and simultaneously published in the New England Journal of Medicine (NEJM).

"The data presented at EHA and published in NEJM underscore the consistent, durable and transformative benefits CASGEVY can provide to people living with sickle cell disease or transfusion-dependent beta thalassemia from early in life," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex.

"Despite optimized supportive therapy, children living with sickle cell disease and transfusion‑dependent beta thalassemia carry a significant disease burden from a very young age, with progressive complications leading to the irreversible and life-shortening consequences of these diseases," said Franco Locatelli, M.D., Ph.D., Professor of Pediatrics at the Catholic University of the Sacred Heart of Rome, Director of the Department of Pediatric Hematology and Oncology at Bambino Gesù Children's Hospital, Chair of Vertex's TDT Program Steering Committee, and presenting author of the 5–11 years old CASGEVY data at EHA. "These data represent a profoundly important step forward, and I look forward to the possibility of providing earlier intervention to prevent complications in children and for families who have had limited potentially curative options to date."

CASGEVY clinical data for children ages 5–11 presented at EHA and published in NEJM

Story Continues

Data from an interim analysis of the CLIMB-151 and CLIMB-141 studies highlight the transformative potential CASGEVY can provide to children ages 5–11 and are consistent with the durable clinical profile established in adult and adolescent patients. Collectively, these findings highlight the potential benefits of addressing vaso-occlusive crises (VOCs) and transfusion burden earlier in life, which can begin in childhood and are associated with cumulative, long-term complications in SCD and TDT including organ damage.

In the Phase 3 CLIMB-151 clinical study of children with severe SCD, all 11 patients dosed are free from VOCs and all 8 out of 8 (100%) patients with sufficient follow-up achieved the primary endpoint of being free from VOCs for at least 12 consecutive months (VF12). Of children achieving VF12, the mean (min, max) duration VOC-free was 19.0 (13.2, 30.1) months. In the Phase 3 CLIMB-141 clinical study of children with TDT, 15 patients have been dosed with CASGEVY, and all 8 out of 8 (100%) patients with sufficient follow-up achieved the primary endpoint of transfusion independence for at least 12 consecutive months while maintaining a weighted average hemoglobin of at least 9 g/dL (TI12). All children who achieved TI12 remained so throughout the follow-up; the mean (min, max) duration transfusion independence was 23.4 (13.3, 28.5) months. The safety profile of CASGEVY in younger patients is consistent with myeloablative conditioning and autologous transplant, as established in clinical studies in older patients with SCD and TDT.

As previously disclosed, there was one death, not related to CASGEVY, in a child with TDT who developed severe veno-occlusive disease from busulfan conditioning. Consistent with studies in older patients, children with severe SCD and TDT treated with CASGEVY have durable and clinically relevant increases in fetal hemoglobin (HbF) and stable allelic editing.

Global regulatory submissions to expand use of CASGEVY

CASGEVY is currently approved for eligible people 12 years and older with SCD with recurrent VOCs or TDT in several countries around the world. In the United States the regulatory review is underway with the FDA to expand the use of CASGEVY to younger children after Vertex was awarded the Commissioner's National Priority Voucher. Vertex has also recently completed regulatory submissions in the Kingdom of Saudi Arabia and United Kingdom to expand the use of CASGEVY to younger children. Upon availability, there is an established network of activated authorized treatment centers in these countries prepared to support patients.

The use of CASGEVY in children ages 5–11 years is investigational.

About Sickle Cell Disease (SCD)

Sickle Cell Disease (SCD) is a rare serious, inherited blood disease that is progressive and life‑shortening. The disease causes red blood cells to become rigid and misshapen, restricting blood flow and oxygen delivery to vital organs. Recurrent vaso‑occlusive crises (VOCs), unpredictable episodes of severe pain caused by blocked blood vessels, are a defining feature of SCD and frequently require hospitalization. Many patients experience these complications early in life, and over time, repeated VOCs and chronic anemia lead to progressive and irreversible organ damage, including damage to the brain, lungs, kidneys and heart. SCD places a substantial burden on patients and their families, who must manage frequent medical visits, hospitalizations, school and work disruptions, and the emotional toll of chronic pain and life‑threatening complications. Despite lifelong treatment, people with SCD and recurrent VOCs in Europe face shortened life expectancy, with a mean age of death of around 40 years, and report quality‑of‑life outcomes far below the general population.

About Transfusion‑Dependent Beta Thalassemia (TDT)

Transfusion‑dependent beta thalassemia (TDT) is a rare serious, inherited blood disease that is progressive and life‑shortening. The disease impairs the body's ability to produce sufficient hemoglobin, limiting oxygen delivery to tissues and organs. People with TDT do not have enough functional hemoglobin in their red blood cells and require regular, lifelong blood transfusions, often beginning early in childhood, along with ongoing iron chelation therapy. While transfusions are necessary for survival, many of the long‑term complications of TDT are exacerbated by chronic transfusion therapy and iron overload and cumulative damage to the heart, liver and endocrine system, as well as bone abnormalities and delayed growth and puberty. TDT places a significant and ongoing burden on patients and their families, requiring frequent medical visits and complex lifelong treatment. Despite lifelong treatment, people with TDT face shortened life expectancy, with a mean age of death of approximately 50–55 years in Europe, reduced quality of life and productivity, and significant use of health care resources.

About CASGEVY® (exagamglogene autotemcel)

CASGEVY is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient's own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown in clinical trials to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT.

About the CLIMB Studies

The completed Phase 1/2/3 open-label studies, CLIMB-111 and CLIMB-121, were designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12–35 years with TDT or with SCD and recurrent VOCs. Patients were followed for approximately two years after CASGEVY infusion in these studies. CLIMB-141 and CLIMB-151 are ongoing Phase 3 open-label studies, designed to assess the safety and efficacy of a single dose of exagamglogene autotemcel in patients ages 2–11 years with TDT or with SCD and recurrent VOCs. Enrollment and dosing are complete for the 5–11-year-old cohort in both studies.

Each patient in these studies is asked to participate in the ongoing long-term, open-label study, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients with up to 15 years of follow-up after CASGEVY infusion.

U.S. INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR CASGEVY

WHAT IS CASGEVY?

CASGEVY is a one-time therapy used to treat people ages 12 years and older with:

• sickle cell disease (SCD) who have frequent vaso-occlusive crises or VOCs

• beta thalassemia (β-thalassemia) who need regular blood transfusions

CASGEVY is made specifically for each patient, using the patient's own edited blood stem cells, and increases the production of a special type of hemoglobin called hemoglobin F (fetal hemoglobin or HbF). Having more HbF increases overall hemoglobin levels and has been shown to improve the production and function of red blood cells. This can eliminate VOCs in people with sickle cell disease and eliminate the need for regular blood transfusions in people with beta thalassemia.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about CASGEVY?

After treatment with CASGEVY, you will have fewer blood cells for a while until CASGEVY takes hold (engrafts) into your bone marrow. This includes low levels of platelets (cells that usually help the blood to clot) and white blood cells (cells that usually fight infections). Your doctor will monitor this and give you treatment as required. The doctor will tell you when blood cell levels return to safe levels.

Tell your healthcare provider right away if you experience any of the following, which could be signs of low levels of platelet cells:

severe headache abnormal bruising prolonged bleeding bleeding without injury such as nosebleeds; bleeding from gums; blood in your urine, stool, or vomit; or coughing up blood Tell your healthcare provider right away if you experience any of the following, which could be signs of low levels of white blood cells:

fever chills infections

You may experience side effects associated with other medicines administered as part of the treatment regimen for CASGEVY. Talk to your physician regarding those possible side effects. Your healthcare provider may give you other medicines to treat your side effects.

How will I receive CASGEVY?

Your healthcare provider will give you other medicines, including a conditioning medicine, as part of your treatment with CASGEVY. It's important to talk to your healthcare provider about the risks and benefits of all medicines involved in your treatment.

After receiving the conditioning medicine, it may not be possible for you to become pregnant or father a child. You should discuss options for fertility preservation with your healthcare provider before treatment.

STEP 1: Before CASGEVY treatment, a doctor will give you mobilization medicine(s). This medicine moves blood stem cells from your bone marrow into the blood stream. The blood stem cells are then collected in a machine that separates the different blood cells (this is called apheresis). This entire process may happen more than once. Each time, it can take up to one week.

During this step rescue cells are also collected and stored at the hospital. These are your existing blood stem cells and are kept untreated just in case there is a problem in the treatment process. If CASGEVY cannot be given after the conditioningmedicine, or if the modified blood stem cells do not take hold (engraft) in the body, these rescue cells will be given back to you. If you are given rescue cells, you will not have any treatment benefit from CASGEVY.

STEP 2: After they are collected, your blood stem cells will be sent to the manufacturing site where they are used to make CASGEVY. It may take up to 6 months from the time your cells are collected to manufacture and test CASGEVY before it is sent back to your healthcare provider.

STEP 3: Shortly before your stem cell transplant, your healthcare provider will give you a conditioning medicine for a few days in hospital. This will prepare you for treatment by clearing cells from the bone marrow, so they can be replaced with the modified cells in CASGEVY. After you are given this medicine, your blood cell levels will fall to very low levels. You will stay in the hospital for this step and remain in the hospital until after the infusion with CASGEVY.

STEP 4: One or more vials of CASGEVY will be given into a vein (intravenous infusion) over a short period of time.

After the CASGEVY infusion, you will stay in hospital so that your healthcare provider can closely monitor your recovery. This can take 4-6 weeks, but times can vary. Your healthcare provider will decide when you can go home.

What should I avoid after receiving CASGEVY?

Do not donate blood, organs, tissues, or cells at any time in the future

What are the possible or reasonably likely side effects of CASGEVY?

The most common side effects of CASGEVY include:

Low levels of platelet cells, which may reduce the ability of blood to clot and may cause bleeding Low levels of white blood cells, which may make you more susceptible to infection

Your healthcare provider will test your blood to check for low levels of blood cells (including platelets and white blood cells). Tell your healthcare provider right away if you get any of the following symptoms:

fever chills infections severe headache abnormal bruising prolonged bleeding bleeding without injury such as nosebleeds; bleeding from gums; blood in your urine, stool, or vomit; or coughing up blood

These are not all the possible side effects of CASGEVY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of CASGEVY

Talk to your healthcare provider about any health concerns.

Please see full Prescribing Information including Patient Information for CASGEVY.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.

Vertex Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements made by Carmen Bozic, M.D., and Franco Locatelli, M.D., Ph.D., and statements regarding expectations for the transformative potential of CASGEVY in this age group, and expectations for the global regulatory submissions for younger children. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy or other reasons, that CASGEVY may not receive regulatory approval for this age range on the expected timeline, or at all, and other risks listed under the heading "Risk Factors" in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company's website at www.vrtx.com. You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610130971/en/

Contacts

Vertex Pharmaceuticals Incorporated

Investors: InvestorInfo@vrtx.com or +1 617-341-6108

Media: mediainfo@vrtx.com or 617-341-6992

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Mit allen Rechnungen sollte CRISPR Therapeutics-Aktien fliegen. Das Unternehmen hat die Rechte an einer der wenigen genehmigten Gene-Editierungstherapien im Gesundheitswesen und mehrere weitere in Arbeit. Die Interesse an seiner einzigen genehmigten Behandlung ist solid, auch wenn ein hoher Preis von 2,2 Millionen Dollar pro Patienten fällt. Über 500 Menschen haben zumindest begonnen, seine einzige markierte Therapie zu verwenden, die erst im späten 2023 genehmigt wurde. Das Schulden-schwere Unternehmen mit einem Wert von 5,5 Milliarden Dollar hat über 2,4 Milliarden Dollar an Liquidität und Analysten konsenspreisziel von 80,62 Dollar ist 40% über dem aktuellen Preis der Aktie.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Vancouver, British Columbia--(Newsfile Corp. - 8. Juni 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ('PreveCeutical'), ein Gesundheitsunternehmen, das innovative Optionen für vorbeugende und curative Therapien mit organischen und naturidentischen Produkten entwickelt, gab heute bekannt, dass BioGene Therapeutics Inc. (die 'Gesellschaft' oder 'BioGene') einen bedeutenden Aktionär von, Ty Howton zum Board of Directors ernannt hat, der sofort wirksam ist. Herr Howton verfügt über umfangreiche Erfahrung in der Aufsicht und im Governance-Bereich, nachdem er zuvor als Rechtsberater und Corporate Secretary für Solid Biosciences, AavantiBio, Sarepta Therapeutics und Vertex Pharmaceuticals sowie als Berater zum Board of Health Care Compliance bei Genentech tätig war. Er ist derzeit Mitglied des Vorstands von Make-A-Wish Massachusetts und Rhode Island (seit März 2021).

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Vertex Pharmaceuticals (VRTX) zieht die Aufmerksamkeit der Investoren auf sich, nachdem das Aktienkurs um US$446,83 schwankte. Die Renditen sind gemischt, während die langfristige Entwicklung im Gegensatz zu den kürzeren Perioden steht. Der Wert von Vertex liegt bei 4 und der angegebene intrinsische Rabatt beträgt 45,62 %. Die Frage ist, ob dies ein unterbewerteter Biotech-Leader darstellt oder ob das Markt bereits zukünftige Wachstum einpreist.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Cystische Fibrose (CF) ist eine seltene, lebensbedrohliche genetische Erkrankung, die über 112.000 Menschen weltweit betrifft, darunter etwa 97.000 in den USA, Europa, Australien und Kanada. CF ist eine fortschreitende, multiorganische Krankheit, die die Lungen, Leber, Pankreas, Verdauungstrakt, Nasennebenhöhlen, Schweißdrüsen und Fortpflanzungsorgane betrifft. CF wird durch einen defekten oder fehlenden CFTR-Protein verursacht, der durch bestimmte Mutationen im CFTR-Gen entsteht. Kinder müssen zwei defekte CFTR-Gene - eines von jedem Elternteil - erben, um CF zu haben, und diese Mutationen können durch eine genetische Testung identifiziert werden. Während es viele verschiedene Arten von CFTR-Mutationen gibt, die das Krankheit verursachen können, sind die meisten Menschen mit CF mindestens ein F508del-Mutation besitzen. Die defekte Funktion und/oder Abwesenheit des CFTR-Proteins führt zu einer schlechten Flüssigkeitsfluss in und aus den Zellen in mehreren Organen. In den Lungen führt dies zum Aufbau von abnormalem dickem, klebrigen Schleim, chronischen Lungenerkrankungen und fortschreitender Lungenzerstörung, die letztendlich zum Tod für viele Patienten führt. Die Median-Altersdifferenz ist in den 30ern, aber mit Behandlung verbessert sich das überlebenspotenzial. Heute werden Vertex-CF-Medikamente über 75.000 Menschen mit CF weltweit behandelt, was etwa 2/3 der diagnostizierten Personen mit CF umfasst, die für CFTR-Modulator-Therapie geeignet sind.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Künstliche Intelligenz wird zu einem der größten Widersprüche auf dem Markt. Der Präsident von Uber Technologies, Andrew Macdonald, sagte in einem Podcast, dass die Firma keine klare Rendite aus der verstärkten Verwendung von KI-Coding-Tools sehen kann. Dies gibt Kritikern neue Argumente, insbesondere wenn sie auf steigende Kosten hinweisen und behaupten, dass der Boom möglicherweise übertrieben ist. Doch die andere Seite des Handels ist immer noch am Leben. Anthropic erhielt 65 Milliarden Dollar bei einer Bewertung von 965 Milliarden Dollar am Donnerstag, was darauf hindeutet, dass Investoren immer noch bereit sind, viel Geld für eine Technologie auszugeben, die sie glauben könnte die Wirtschaft umgestalten. Die Tension bedeutet nicht, dass beide Seiten recht haben können. Die aktuellen Ökonomie von KI mag schwierig sein, insbesondere für Vorhut-Labors, die auf einer Skala Geld verlieren, die größer erscheint als frühes Amazon.com oder Uber. Der CEO von OpenAI, Sam Altman, hat zugegeben, dass das Unternehmen mehr Geld verliert, weil seine schwersten Benutzer viel mehr konsumieren als sie bezahlen. Die Geschichte gibt den Investoren eine nützliche Warnung. Die Luftfahrt hat die Welt verändert, aber Kapital für Jahrzehnte verbrannt, während Biotechnologie echte Durchbrüche erzielte, aber schwache Industrieprofitte von den 1970er Jahren bis in die frühen 2000er Jahre produzierte. Harvards Gary Pisano zeigte, dass viel der öffentlichen Biotech-Unternehmensgewinnbeteiligung bis 2004 aus Amgen kam, während der Rest des Sektors insgesamt unrentabel blieb. Die Investitionsempfehlung lautet nicht, KI zu verwerfen, sondern sich auf eine Strategie zu konzentrieren, die in beiden Ergebnissen erfolgreich sein kann: Eigentum an Daten, Verteilung, Kundenvertrauen und regulatorische Glaubwürdigkeit. Vertex Pharmaceuticals bietet ein nützliches Beispiel aus der Biotechnologie, wo das Unternehmen neue Technologie als Verstärker und nicht als Ersatz für Kernfähigkeiten betrachtete. Wenn KI eine normale Technologie wie Strom wird, könnte Wert möglicherweise zu den Unternehmen fließen, die über die stärksten ergänzenden Vermögenswerte verfügen. Wenn die führenden KI-Labors die meisten Ökonomien erlangen, wird der Spielplan schwieriger. Bis das Ergebnis sichtbarer wird, mögen Investoren auf Unternehmen konzentriert sein wollen, die von KI profitieren können, ohne sich vollständig auf ihre aktuellen Ökonomie zu verlassen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investoren, die zwischen Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) und State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH) wählen, können die geringeren Kosten und breitere Diversifikation von IBBQ gegenüber der etablierten Größe und pharmazeutischen Ausrichtung von XPH abwägen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Beide Unternehmen haben sich dieses Jahr im roten Bereich bewegt. Sie haben jedoch Qualitäten, die ihnen helfen können, wieder aufzubauen. Einige Investoren vermeiden derzeit den Gesundheitssektor, da er in den letzten Jahren hinter dem Markt zurückgeblieben ist und ein unsichertes Ausblick hat. Dieser negativen Stimmung könnte jedoch bedeuten, dass es attraktive Gelegenheiten gibt, um Aktien von Spitzen-Gesundheitsunternehmen zu kaufen, wenn sie sich im Tief fallen. Hier sind zwei meiner Favoriten: AbbVie (NYSE: ABBV) und Vertex Pharmaceuticals (NASDAQ: VRTX). Diese beiden Unternehmen haben nicht nur hervorragende Geschäftsmodelle, sondern haben auch in die falsche Richtung verlaufen dieses Jahr trotz guter Aussichten, was sie zu exzellenten Aktien macht, die jetzt mit 500 Euro gekauft werden können.